- Home
- WNEB vs CRVS Comparison
WNEB vs CRVS Comparison
Compare WNEB & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- CRVS
- Stock Information
- Founded
- WNEB 1853
- CRVS 2014
- Country
- WNEB United States
- CRVS United States
- Employees
- WNEB N/A
- CRVS N/A
- Industry
- WNEB Savings Institutions
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- WNEB Finance
- CRVS Health Care
- Exchange
- WNEB Nasdaq
- CRVS Nasdaq
- Market Cap
- WNEB 195.7M
- CRVS 305.4M
- IPO Year
- WNEB N/A
- CRVS 2016
- Fundamental
- Price
- WNEB $9.97
- CRVS $3.95
- Analyst Decision
- WNEB Buy
- CRVS Strong Buy
- Analyst Count
- WNEB 3
- CRVS 4
- Target Price
- WNEB $9.75
- CRVS $15.00
- AVG Volume (30 Days)
- WNEB 209.5K
- CRVS 1.2M
- Earning Date
- WNEB 07-22-2025
- CRVS 08-05-2025
- Dividend Yield
- WNEB 2.90%
- CRVS N/A
- EPS Growth
- WNEB N/A
- CRVS N/A
- EPS
- WNEB 0.53
- CRVS N/A
- Revenue
- WNEB $72,966,000.00
- CRVS N/A
- Revenue This Year
- WNEB N/A
- CRVS N/A
- Revenue Next Year
- WNEB $7.94
- CRVS N/A
- P/E Ratio
- WNEB $18.21
- CRVS N/A
- Revenue Growth
- WNEB N/A
- CRVS N/A
- 52 Week Low
- WNEB $6.64
- CRVS $1.75
- 52 Week High
- WNEB $10.08
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- WNEB 62.36
- CRVS 50.43
- Support Level
- WNEB $9.28
- CRVS $3.55
- Resistance Level
- WNEB $10.04
- CRVS $4.09
- Average True Range (ATR)
- WNEB 0.27
- CRVS 0.31
- MACD
- WNEB 0.10
- CRVS -0.03
- Stochastic Oscillator
- WNEB 82.12
- CRVS 49.14
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).